Open Access Articles- Top Results for Gevotroline


File:Gevotroline structure.png
Systematic (IUPAC) name
Clinical data
  • Uncontrolled
PubChem CID 60547
ChemSpider 54579
UNII 7SZ6A2091Q 7pxY
Chemical data
Formula C19H20FN3
309.38 g/mol

Gevotroline (WY-47,384) is an atypical antipsychotic with a tricyclic structure which was under development for the treatment of schizophrenia by Wyeth-Ayerst.[1][2][3] It acts as a balanced, modest affinity D2 and 5-HT2 receptor antagonist and also possesses high affinity for the sigma receptor.[2][4][5][6] It was well-tolerated and showed efficacy in phase II clinical trials but was never marketed.[2][3]

See also


  1. ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9. 
  2. ^ a b c Bristol, James A. (1990). Annual Reports in Medicinal Chemistry (Volume 25). Boston: Academic Press. ISBN 0-12-040525-3. 
  3. ^ a b Stone, T. W.; Stone, Trevor (1996). CNS neurotransmitters and neuromodulators: dopamine. Boca Raton: CRC Press. ISBN 0-8493-7632-7. 
  4. ^ Snyder SH, Largent BL (1989). "Receptor mechanisms in antipsychotic drug action: focus on sigma receptors". The Journal of Neuropsychiatry and Clinical Neurosciences 1 (1): 7–15. PMID 2577720. 
  5. ^ Matheson GK, Guthrie D, Bauer C, Knowles A, White G, Ruston C (January 1991). "Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat". Neuropharmacology 30 (1): 79–87. PMID 1675451. doi:10.1016/0028-3908(91)90046-E. 
  6. ^ Gudelsky GA, Nash JF (February 1992). "Neuroendocrinological and neurochemical effects of sigma ligands". Neuropharmacology 31 (2): 157–62. PMID 1348112. doi:10.1016/0028-3908(92)90026-L.